# A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

> **NCT04489797** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 35 (actual)

## Conditions studied

- Infectious Disease

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT04489797
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-08-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489797, "A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04489797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*